EP
IMDZ

Elkfork Partners’s Immune Design Corp. IMDZ Stock Holding History

Elkfork Partners’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,930
Closed -$32K – 1043
2018
Q2 		$32K Buy
+6,930
New +$27.6K ﹤0.01% 986

Other funds holding IMDZ

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Elkfork Partners's IMDZ Position: Q3 2018 in Review

Elkfork Partners sold out of Immune Design Corp. (IMDZ) in Q3 2018, closing a stake of 6,930 shares — an estimated $32K sold.

Elkfork Partners first reported a position in IMDZ in Q2 2018 and held it in 1 quarter. The position peaked at $32K in Q2 2018. 71 funds tracked by Wall St. Rank hold IMDZ as of Q3 2018.

  • Elkfork Partners reported no remaining Immune Design Corp. position as of Q3 2018 after selling out during the quarter.
  • Elkfork Partners sold 6,930 Immune Design Corp. shares in Q3 2018, an estimated $32K.
  • Elkfork Partners first reported a position in Immune Design Corp. in Q2 2018 and held it in 1 quarter.
  • Elkfork Partners's Immune Design Corp. position peaked at $32K in Q2 2018.
  • 71 funds tracked by Wall St. Rank held Immune Design Corp. as of Q3 2018.

Based on Elkfork Partners's 13F filing for Q3 2018, filed 14 Nov 2018.